Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (August 2020)
31 slides from Sutro Biopharma's investor presentation, August 2020
Slide 1: Company Overview August 2020
Company Overview August 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: The Sutro Vision
The Sutro Vision Changing the Future of Oncology PLATFORM PRODUCTS PARTNERS FINANCIAL RESOURCES XpressCF® and XpressCF+™ 3 Clinical Programs in Premier Collaborations: Cash, cash equivalents, 2018-19 (2 proprietary) and marketable securities • Bristol Myers Squibb balance of $207.0M as of • Precisio
Slide 4: Sutro Clinical Pipeline
Sutro Clinical Pipeline Owned and Partnered Programs Program Discovery Preclinical Phase 1/1B Phase 2/3 Milestone Commercial Rights Updated Clinical Data FolRα - Targeting ADC Expected in 2H 2020 Ovarian and Endometrial Cancer Commence Dose Expansion STRO-002 Phase in 2H 2020 CD74 - Targeting ADC Ly
Slide 5: Encouraging Progress Across Multiple Programs
Encouraging Progress Across Multiple Programs* STRO-002 (FolRα ADC) – OC all comers CC-99712 (BCMA ADC) – MM all comers Dose escalation on-going (30 patients dosed & Dose escalation on-going (cleared 0.5-2.0 mg/kg) 68% remain on study) • N=8 as of June 2020, including 4 patients dosed at 3.0 • Promi
Slide 6: Sutro's Approach
Sutro’s Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates Widening the Therapeutic Index is Key to Achieving Best-in-Class Performance XpressCF® -– Our Truly Empirical Approach Proprietary XpressCF® rapid synthesis protein library generation, precision conjugation technology
Slide 7: FolRα – Targeting ADC Phase 1
STRO 002 FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 8: STRO-002 Phase 1 Clinical Trial Design
STRO 002 Phase 1 Clinical Trial Design Fast Track FDA Registration Pathway Possible Based on Recent Precedent Part 1 — Dose Escalation Part 2 — Dose Expansion (1 Cohort: Ovarian) (2 Cohorts) MTD *DOSE LEVEL n Ovarian STRO-002 6.4mg/kg Up to n=40 Dose Level 6.0mg/kg Dose Level RP2D 5.6mg/kg Dose Leve
Slide 9: Heavily Pretreated: Patient Demographics/Dose Levels
STRO 002 Heavily Pretreated: Patient Demographics/Dose Levels Reported April 27, 2020 (Data as of April 20, 2020) Characteristic Total N = 30 (%) Age, median (range), years 60.5 (47-76) Tumor type EOC 25 (83) Characteristic Total N = 30 (%) Fallopian tube 3 (10) Dose Level of STRO-002 Primary perito
Slide 10: Heavily Pretreated Patients Have Historically Low Response Rates
STRO 002 Heavily Pretreated Patients Have Historically Low Response Rates Literature Suggests Minimal Disease Control in Heavily-Pretreated Patients Source 4th Line 5th Line 6th Line Griffiths 2011 ORR: 3% ORR: 2% ORR: 0% N=274 DCR: 18% DCR: 18% DCR: 3% Hoskins 2005 ORR: 11% ORR: 8% ORR: 0% N=120 DC
Slide 11: Generally Well Tolerated Without Ocular Toxicity Signals
STRO 002 Generally Well Tolerated Without Ocular Toxicity Signals Treatment Emergent AEs in ≥ 20% of Patients (without causality attribution) The emerging STRO-002 safety profile includes mostly mild adverse events - 89% of all AEs reported are grade 1 or 2 Treatment Emergent Adverse Events (TEAE) T
Slide 12: Promising Interim Analysis Demonstrates RECIST Response and Stable Disease
STRO 002 Promising Interim Analysis Demonstrates RECIST Response and Stable Disease in Heavily Pre-Treated Patients 50 Best % change in sum of target lesions from baseline 40 N=20 evaluable patients treated at ≥ 2.9 mg/kg +30 30 +19 +19 2.9 mg/kg 20 % change best response target lesion 4.3 mg/kg Ear
Slide 13: 75% of Patients at ≥2.9 mg/kg Showed Stable Disease or Partial Response
STRO 002 75% (15/20*) of Patients Treated at ≥ 2.9 mg/kg Have Initial Post-Baseline Scans That Showed Stable Disease or Partial Response 103-7001 112-7001 117-7001 115-7001 112-7002 On study 115-7002 113-7001 On study 2.9 mg/kg Evaluable patient 103-7002 4.3 mg/kg 113-7002 On study 5.2 mg/kg benefit
Slide 14: 35% of Evaluable Patients Remained on Study >24 Weeks
STRO 002 35% (7/20) Patients Evaluable for Progression at ≥ 2.9 mg/kg Remained on Study > 24 weeks 7 patients on study 103-7001 112-7001 24 weeks > 24 weeks 117-7001 115-7001 2.9 mg/kg 112-7002 4.3 mg/kg 115-7002 5.2 mg/kg 113-7001 103-7002 5.6 mg/kg 11 patients still on 113-7002 6.0 mg/kg 114-7001
Slide 15: 62% of Patients Had ≥50% Reduction or Normalization of CA-125
62% (13/21) of Patients Treated at ≥ 2.9 mg/kg with Post- STRO 002 Baseline Assessments Had ≥ 50% Reduction or Normalization of CA-125 Y axis- change from C1D1 CA-125 2.9 mg/kg 4.3 mg/kg 1.0 5.2 mg/kg 5.6 mg/kg 6.0 mg/kg 6.4 mg/kg CA-125 Responses 0.5 • 6 confirmed CA-125 responses • 1 sustained CA-
Slide 16: All Patients with CA-125 Response Remain on Study Treatment
STRO 002 All Patients with CA-125 ≥ 50% Reduction or Normalization Remain on Study Treatment and 100% (12/12) Achieved Tumor Control 103-7001 112-7001 117-7001 115-7001 112-7002 Confirmed 115-7002 2.9 mg/kg 113-7001 Normalized 4.3 mg/kg 103-7002 Confirmed 113-7002 5.2 mg/kg CA-125 Responses 114-7001
Slide 17: FolRα Studies with Similar Heavily Pre-Treated Ovarian Cancer Populations
STRO 002 FolRα Studies with Similar Heavily Pre-Treated, Unselected Ovarian Cancer Patient Populations in Phase 1 Dose Escalation STRO-002 (n = 30) Mirvetuximab (n = 44)** XMT-1536 (n=48)*** Ovarian (n = 23) Ovarian (n=37) Endometrial CA (n = 11) NSCLC (n=11) Trial status/ presentation 4/20/20 updat
Slide 18: Anti-Tumor Activity of STRO-002 is Encouraging
STRO 002 Anti-Tumor Activity of STRO-002 is Encouraging STRO-002 (n = 25) ≥ 2.9 mg/kg Mirvetuximab (n = 23)* XMT-1536 (n=43)** 39/44 (89)% Ovarian (34) and NSCLC (9) ≥ 3.3 mg/kg43.3 mg/ ≥ 20 mg/m2 Efficacy Analysis Interim - Ongoing Final Near Final, Data analysis 2/3/20 CA-125 responses • 6 confirm
Slide 19: Anti-Tumor Activity of STRO-002 is Encouraging
STRO 002 Anti-Tumor Activity of STRO-002 is Encouraging 35% of Patients at ≥ 2.9 mg/kg Remain on Study >24 weeks STRO-002 (n = 25) Mirvetuximab (n = 23)* XMT-1536 (n=43)** ≥ 2.9/mg Ovarian (34) and NSCLC (9) ≥ 20 mg/m2 Remaining on study treatment 68% of patients None 12% of patients (5/43) On study
Slide 20: CD74-Targeting ADC: Phase 1
STRO 001 CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 21: STRO-001 Phase 1 Clinical Trial Design
STRO 001 Phase 1 Clinical Trial Design Part 1 — Dose Escalation (2 Cohorts) Part 2 — Dose Expansion (4 Potential Cohorts) 21-day cycle Refractory Multiple Myeloma Dosing Q3W MTD DOSE LEVEL n Advanced and/or Multiple Myeloma Dose Level 2 Up to n=40 RP2D N=30 Dose Level 1 DLBCL MTD Up to n=40 21-day c
Slide 22: Patient Demographics
STRO 001 Patient Demographics First 25 Patients – ASH Abstract November 2019 Characteristics Cohort A (MM) Cohort B (NHL) Total N =14 N=11 N=25 Age, median (range), years 64.5 (42-80) 64 (21-82) 64 (21-82) Median time from diagnosis in years (range) 6.4 (1.3-13.6) 3.2 (1.0-29.8) 6.2 (1.0-29.8) Disea
Slide 23: Generally Well Tolerated with Early Signs of Anti-Tumor Activity
STRO 001 Generally Well Tolerated with Early Signs of Anti-Tumor Activity Presented at EHA June 2019 and Updated in ASH Abstract November 2019 • STRO-001 was generally well tolerated, most AEs were Grade 1 & 2 • No ocular toxicity signals have been observed • Preliminary anti-tumor activity: DLBCL:
Slide 24: CC-99712 (BCMA-Targeting ADC) Phase 1B/2 Study
CC–99712 (BCMA-Targeting ADC) Phase 1B/2 Study Potential for Best-In-Class CC-99712 Molecule Ongoing Study of Dose Escalation (Q3W) Site-specific conjugation leads to Drug-antibody Ratio (DAR) = 4 DL7 10.0 mg/kg DL6 6.7 mg/kg N=3-6 DL5 4.5 mg/kg N=4 DL4 3.0 mg/kg O O O O O O O N=2 DL3 2.0 mg/kg O O
Slide 25: M1231 (MUC1-EGFR Bispecific ADC)
M1231 (MUC1-EGFR Bispecific ADC) Potential for First-In-Class – 1Q21 First In Man Planned • First bispecific ADC targeting MUC1 & EGFR EGFR • Combines next generation technologies; stable site-specific conjugation with nnAA, optimized positioning of a proprietary MUC1 hemiasterlin payload, SEED anti
Slide 26: M1231 Strong Efficacy in Preclinical PDX Models
M1231 (MUC1-EGFR Bispecific ADC) Strong efficacy in preclinical NSCLC & esophageal cancer PDX models • A single M1231 application was associated with complete remission in a subset of preclinical NSCLS and sqCC esophageal PDX models • Tumor response seems to be associated with target expression Ande
Slide 27: Sutro's Next Generation Tumor Targeting Immunostimulatory ADC
iADC Sutro’s Next Generation Tumor Targeting Immunostimulatory ADC – Off the shelf, systemically administered in situ immunization • Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate • Designed and enabled using Sutro’s XpressCF+TM platform • Enables simultaneous
Slide 28: Enhanced Immune Cell Activation and Anti-Tumor Immunity
iADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity MC38-hFolR mouse model iADC single dose causes iADC treated mice resistant to some complete responses future re-challenge Control (iADC) ISAC (TLR agonist alone) ADC (Cytotoxin alone) iADC (Cytotoxin + TLR agonist) Early activatio
Slide 29: Delivering On Our XpressCF+ Collaborations
Delivering On Our XpressCF+TM Collaborations ~ $370 Million in Payments Received through 2019 from Collaborators BCMA-targeting ADC (CC-99712): IND Anticipated in 2H2021: • Phase 1b/2 trial for multiple myeloma (dose escalation began 2H • Formerly SutroVax – spinout using XpressCF+™ 2019) • Potentia
Slide 30: Experienced Leadership Team
Experienced Leadership Team Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Scientific Officer MD, MS, FACP Chief Financial Officer Chief Medical Officer William Newell, JD Chief Executive Officer and Member of the Board of Directors Shabbir Anik, PhD Linda Fitzpatrick Nicki Vasquez, PhD Chief Tec
Slide 31: Company Overview August 2020
Company Overview August 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Sutro Biopharma — Investor Presentation (August 2020) on 6ix